Pharma

​​REDEFINE 2 Phase 3 trial showed CagriSema led to a 15.7% weight loss in adults with obesity and type 2 diabetes, but the results fell short of expectations, causing a decline in the company's stock value.

The acquisition of Chimerix for $935 million will enhance Jazz’s oncology portfolio, particularly through the addition of dordaviprone, a lead drug candidate for treating a rare and aggressive brain tumor.

New US study evaluates the cost-effectiveness of semaglutide in treating non-diabetic patients with obesity and cardiovascular disease.

Pfizer has announced it will no longer develop or sell Beqvez, its hemophilia B gene therapy, in any global markets.

Moderna reported sales of $3.1 billion, the comapny states this is a 53% decline from 2023. Read about the steps being taken to combat this decline in performance.

Dupixent has received FDA priority review for the treatment of bullous pemphigoid, a rare autoimmune skin disorder. If approved, Dupixent would become the first targeted therapy for BP, offering a safer and more effective treatment option.